Literature DB >> 24076507

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

Han Ma1, Anne Dallas2, Heini Ilves2, Joshua Shorenstein2, Ian MacLachlan3, Klaus Klumpp1, Brian H Johnston4.   

Abstract

Short synthetic hairpin RNAs (sshRNAs) (SG220 and SG273) that target the internal ribosome entry site of the hepatitis C virus (HCV) were formulated into lipid nanoparticles and administered intravenously to HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopulated with human hepatocytes (humanized livers). Weekly administration of 2.5 mg/kg of each sshRNA for 2 weeks resulted in a maximal mean reduction in viral load of 2.5 log10 from baseline. The viral load remained reduced by more than 90% at 14 days after the last dose was given. The sshRNAs were well tolerated and did not significantly increase liver enzyme levels. These findings indicate the in vivo efficacy of a synthetic RNA inhibitor against the HCV genome in reducing HCV infection.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCV; IRES; LNP; PBS; RNA Interference; RNA interference; RNAi; RPA; Short shRNA; hepatitis C virus; internal ribosome entry site; lipid nanoparticle; phosphate-buffered saline; ribonuclease protection assay; short synthetic hairpin RNA; siRNA; sshRNA; uPA-SCID; uPA-SCID Chimeric Mice; urokinase-type plasminogen activator-severe combined immunodeficiency

Mesh:

Substances:

Year:  2013        PMID: 24076507      PMCID: PMC3896324          DOI: 10.1053/j.gastro.2013.09.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity.

Authors:  Qing Ge; Heini Ilves; Anne Dallas; Pavan Kumar; Joshua Shorenstein; Sergei A Kazakov; Brian H Johnston
Journal:  RNA       Date:  2009-12-01       Impact factor: 4.942

2.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

Authors:  Joseph F Perz; Gregory L Armstrong; Leigh A Farrington; Yvan J F Hutin; Beth P Bell
Journal:  J Hepatol       Date:  2006-06-23       Impact factor: 25.083

3.  A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.

Authors:  Lloyd B Jeffs; Lorne R Palmer; Ellen G Ambegia; Cory Giesbrecht; Shannon Ewanick; Ian MacLachlan
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Authors:  Qing Ge; Anne Dallas; Heini Ilves; Joshua Shorenstein; Mark A Behlke; Brian H Johnston
Journal:  RNA       Date:  2009-11-30       Impact factor: 4.942

Review 6.  The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

Authors:  Philip Meuleman; Geert Leroux-Roels
Journal:  Antiviral Res       Date:  2008-08-14       Impact factor: 5.970

7.  Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs.

Authors:  Takanori Yokota; Naoya Sakamoto; Nobuyuki Enomoto; Yoko Tanabe; Makoto Miyagishi; Shinya Maekawa; Li Yi; Masayuki Kurosaki; Kazunari Taira; Mamoru Watanabe; Hidehiro Mizusawa
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

8.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region.

Authors:  Joyce A Wilson; Christopher D Richardson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.

Authors:  Niu Shi; Nobuhiko Hiraga; Michio Imamura; C Nelson Hayes; Yizhou Zhang; Keiichi Kosaka; Akihito Okazaki; Eisuke Murakami; Masataka Tsuge; Hiromi Abe; Hiroshi Aikata; Shoichi Takahashi; Hidenori Ochi; Chise Tateno-Mukaidani; Katsutoshi Yoshizato; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Min Gao; Kazuaki Chayama
Journal:  Gut       Date:  2013-01-15       Impact factor: 23.059

View more
  15 in total

1.  Toward optimization of AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the top and bottom base pairs.

Authors:  Elena Herrera-Carrillo; Alex Harwig; Ben Berkhout
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

2.  Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Authors:  Emily P Thi; Chad E Mire; Raul Ursic-Bedoya; Joan B Geisbert; Amy C H Lee; Krystle N Agans; Marjorie Robbins; Daniel J Deer; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2014-08-20       Impact factor: 17.956

Review 3.  Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.

Authors:  Jinho Park; Joonyoung Park; Yihua Pei; Jun Xu; Yoon Yeo
Journal:  Adv Drug Deliv Rev       Date:  2015-12-10       Impact factor: 15.470

Review 4.  Nanomedicine based approaches for combating viral infections.

Authors:  Saurabh Shah; Mahavir Bhupal Chougule; Arun K Kotha; Rama Kashikar; Chandraiah Godugu; Rajeev Singh Raghuvanshi; Shashi Bala Singh; Saurabh Srivastava
Journal:  J Control Release       Date:  2021-08-08       Impact factor: 11.467

5.  Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Authors:  Emily P Thi; Amy C H Lee; Joan B Geisbert; Raul Ursic-Bedoya; Krystle N Agans; Marjorie Robbins; Daniel J Deer; Karla A Fenton; Andrew S Kondratowicz; Ian MacLachlan; Thomas W Geisbert; Chad E Mire
Journal:  Nat Microbiol       Date:  2016-08-22       Impact factor: 17.745

6.  Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.

Authors:  Anne Dallas; Heini Ilves; Han Ma; Daniel J Chin; Ian Maclachlan; Klaus Klumpp; Brian H Johnston
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

7.  siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Authors:  Emily P Thi; Chad E Mire; Amy Ch Lee; Joan B Geisbert; Raul Ursic-Bedoya; Krystle N Agans; Marjorie Robbins; Daniel J Deer; Robert W Cross; Andrew S Kondratowicz; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  J Clin Invest       Date:  2017-11-06       Impact factor: 14.808

8.  Acceleration of Diabetic Wound Healing with PHD2- and miR-210-Targeting Oligonucleotides.

Authors:  Anne Dallas; Artem Trotsyuk; Heini Ilves; Clark A Bonham; Melanie Rodrigues; Karl Engel; Janos A Barrera; Nina Kosaric; Zachary A Stern-Buchbinder; Aleksandr White; Kenneth J Mandell; Paula T Hammond; Jonathan Mansbridge; Sumedha Jayasena; Geoffrey C Gurtner; Brian H Johnston
Journal:  Tissue Eng Part A       Date:  2018-06-29       Impact factor: 3.845

9.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 10.  Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.

Authors:  Mohamed Shehata Draz; Binbin Amanda Fang; Pengfei Zhang; Zhi Hu; Shenda Gu; Kevin C Weng; Joe W Gray; Fanqing Frank Chen
Journal:  Theranostics       Date:  2014-06-11       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.